Premium
Aiming for better glucose control: is HbA 1c of 7% the ‘holy grail’? The clinical approach or seven clinical questions about 7
Author(s) -
Koren Shlomit,
Rapoport Micha J.
Publication year - 2014
Publication title -
diabetes/metabolism research and reviews
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.307
H-Index - 110
eISSN - 1520-7560
pISSN - 1520-7552
DOI - 10.1002/dmrr.2532
Subject(s) - holy grail , diabetes mellitus , medicine , control (management) , health care , gerontology , intensive care medicine , economics , computer science , economic growth , endocrinology , management , world wide web
Summary The diabetes epidemic imposes a substantial burden on health systems and economy all over the world. Over the last two decades, many health systems adopted health care quality and performance measures for diabetes mellitus, most notably haemoglobin A 1c . This article raises concerns regarding the significance of HbA 1c as a performance measure and emphasizes the need for individualized therapy. Copyright © 2014 John Wiley & Sons, Ltd.